| Autor: |
DeJesus, Edwin, Herrera, Gisela, Teofilo, Eugenio, Jan Gerstoft, Buendia, Carlos Beltran, Brand, J. David, Brothers, Cynthia H., Hernandez, Jaime, Castillo, Steve A., Bonny, Tab, Lanier, E. Randall, Scott, Trevor R. |
| Předmět: |
|
| Zdroj: |
Clinical Infectious Diseases; 10/1/2004, Vol. 39 Issue 7, p1038-1046, 9p |
| Abstrakt: |
Background. Zidovudine, lamivudine, and efavirenz comprise a highly effective and well-tolerated triple regimen for antiretroviral-naive patients. Evaluating other unique nucleoside reverse-transcriptase inhibitor(NRTI) combinations for long-term viral suppression is desirable. Methods. This multicenter, randomized, double-blind noninferiority clinical trial compared the efficacy and safety of abacavir with that of zidovudine plus lamivudine and efavirenz in 649 antiretroviral-naive HIV-infected patients. The primary objective was a comparison of proportions of patients achieving plasma HIV-1 RNA levels <50 copies/mL through week 48 of the study. Results. At study week 48, 70% of patients in the abacavir group, compared with 69% in the zidovudine group, maintained confirmed plasma HIV-1 RNA levels of <50 copies/mL (in the intent-to-treat exposed population). Virologic failure was infrequent (6% in the abacavir group and 4% in the zidovudine group). There was a significant CD4+ cell response (209 cells/mm³ in the abacavir group and 155 cells/mm³ in the zidovudine group). Safety profiles were as expected. Conclusion. Abacavir provided an effective and durable antiretroviral response that was noninferior to zidovudine, when combined with lamivudine and efavirenz. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
